Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Dec 1;64(12):6192-6200.
doi: 10.1093/rheumatology/keaf341.

Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: a multicentre retrospective study

Arsène Mekinian  1 , Sarah Meneses  2 , Lucie Biard  2 , Lorenzo Dagna  3 , Pavel Novikov  4 , Carlo Salvarani  5 , Olivier Espitia  6 , Savino Sciscia  7 , Martin Michaud  8 , Marc Lambert  9 , José Hernández-Rodríguez  10 , Nicolas Schleinitz  11 , Abid Awisat  12 , Xavier Puéchal  13 , Achille Aouba  14 , Heloise Munoz Pons  15 , Ilya Smitienko  16 , Jean Baptiste Gaultier  17 , Le Mouel Edwige  18 , Ygal Benhamou  19 , Antoinette Perlat  18 , Patrick Jego  18 , Tiphaine Goulenok  20 , Karim Sacre  20 , Bertrand Lioger  21 , Nolan Hassold  22 , Jonathan Broner  23 , Virginie Dufrost  24 , Thomas Sene  25 , Julie Seguier  26 , Francois Maurier  27 , Sabine Berthier  28 , Alexandre Belot  29 , Faten Frikha  30 , Guillaume Denis  31 , Alexandra Audemard-Verger  32 , Isabelle Koné-Paut  22 , Sebastien Humbert  33 , Pascal Woaye-Hune  34 , Alessandro Tomelleri  3 , Elena Baldissera  3 , Masataka Kuwana  35 , Alberto Lo Gullo  36 , Vahan Mukuchyan  37 , Azeddine Dellal  38 , Francis Gaches  8 , Pierre Zeminsky  24 , Chiara Marvisi  5 , Moya Alvarado  5 , Luigi Boiardi  5 , Francesco Muratore  5 , Mathieu Vautier  2 , Corrado Campochiaro  3 , Sergey Moiseev  4 , Matheus Vieira  39 , Patrice Cacoub  39 , Olivier Fain  1 , David Saadoun  39 ; French Takayasu Network
Collaborators, Affiliations
Comparative Study

Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: a multicentre retrospective study

Arsène Mekinian et al. Rheumatology (Oxford). .

Abstract

Objectives: In this large multicentre study, we aimed to compare the effectiveness of intravenous infliximab (IFX) vs subcutaneous adalimumab (ADA) in patients with Takayasu arteritis (TAK).

Methods: We conducted a retrospective multicentre study across referral centres in France, Italy, Spain, Armenia, Israel, Japan, Tunisia, and Russia, analysing biologic targeted therapies in TAK from January 2017 to September 2019.

Results: A total of 135 TAK patients who received ADA (n = 34) or IFX (n = 101) for at least 3 months were included. Baseline demographics, TAK characteristics and concurrent treatments were comparable, except for a higher rate of Numano type V in the ADA group. At 6 months, 71% achieved complete response (NIH <2 with <7.5 mg/day prednisone), including 68% on ADA and 73% on IFX (P = 0.8). The factors associated with complete response to TNF-α inhibitors at 6 months in univariate analysis were age <30 years, tobacco use, vascular signs at the biologic initiation, NIH ≥2, CRP >20 mg/l, a starting dose >20 mg/day of prednisone, but not the use of either IFX or ADA. The cumulative incidence of treatment failure was not significantly different between IFX and ADA patients. During the median [IQR] follow-up of 23 [17, 42] and 48 [25, 99] months in patients who received i.v. IFX and s.c. ADA, respectively, the risk of relapse at 12 months was 10.9% [0, 21.9] and 16.8% [8.64, 24.27], respectively. The overall incidence of revascularizations was not significantly different.

Conclusion: In this study, we confirm that IFX and ADA are both effective in TAK, without significant differences in the risk of relapse and revascularizations.

Keywords: TNF-α; Takayasu arteritis; inhibitors; vasculitis treatment.

PubMed Disclaimer